Sofinnova Investments related stories
All articles and analysis
Checkmate Pharma raises $20 mlnCheckmate Pharmaceuticals said Tuesday that it raised $20 million in Series A financing from Sofinnova Ventures and venBio. Checkmate is a biopharmaceutical company aimed at developing cancer immunotherapies.
- Antiva Biosciences nabs $16 mln Series B
Biopharmaceutical company Antiva Biosciences Inc has secured $16 million in Series B funding. Canaan Partners and Sofinnova Ventures led the round. In conjunction with the funding, Wende Hutton, a general partner at Canaan Partner and David Kabakoff, an executive partner at Sofinnova Ventures, have been added to Antiva's board of directors. Also, the company has named Gail Maderis as president and CEO and Steven P. James as executive chairman of the board.
IPO Aftermarket: Fitbit surge dominates headlines, as biotech companies continue to roll outThrough the end of June, 42 VC-backed companies have gone public on the NYSE or Nasdaq exchanges
- VC-backed aTyr Pharma rolls out IPO
San Diego-based biotherapeutics company aTyr Pharma Inc has debuted its IPO after pricing its 5.36 million shares at $14 per share. The stock began trading Thursday on the NASDAQ under the ticker symbol "LIFE." J.P. Morgan Securities LLC and Citigroup Global Markets are serving as the lead underwriters. The company’s backers include Alta Partners, Cardinal Partners, Domain Associates, Polaris Partners, Sofinnova Ventures, T. Rowe Price Associates Inc, Federated Investors Inc, Deerfield, Rock Springs Capital Management, EcoR1 Capital and Sphera Global Healthcare.
- Edge Therapeutics racks up about $72.5 mln
Berkeley Heights, New Jersey-based Edge Therapeutics, a biotech company focused on developing therapies for neurological conditions, has secured about $72.5 million in funding from two recent rounds. The company just closed $56 million in a Series C-2 funding round led by Venrock with participation from other investors that included Sofinnova Ventures, Janus Capital Management LLC, New Leaf Venture Partners and BioMed Ventures. The earlier round, which closed in December 2014, raised $16.5 million in Series C-1 funding. The investors for that round were not named. In connection to the Series C-2 round, Dr. Anders Hove of Venrock and Dr. James Healy, a managing partner at Sofinnova Ventures, have been added to Edge Therapeutics' board of directors.
- VC-backed aTyr files for IPO
San Diego-based biotherapeutics company aTyr Pharma Inc has filed for an IPO. The number of shares that will be sold as well as the stock's pricing terms have yet to be set. The company plans on trading its stock on the NASDAQ under the ticker symbol "LIFE." J.P. Morgan Securities LLC and Citigroup Global Markets Inc will serve as the lead underwriters. The company's backers include Alta Partners, Cardinal Partners, Domain Associates, Polaris Partners, Sofinnova Ventures, T. Rowe Price Associates Inc, Federated Investors Inc, Deerfield, Rock Springs Capital Management, EcoR1 Capital and Sphera Global Healthcare.
- Atyr Pharma raises $76 mln
Atyr Pharma Inc. said Tuesday it raised $76 million in Series E financing led by new investor Sofinnova Ventures and an undisclosed large institutional investor in the biotechnology industry. Also taking part in the round were T. Rowe Price Associates Inc.; Federated Investors Inc.; Deerfield; Rock Springs Capital Management; EcoR1 Capital; Sphera Global Healthcare and two additional undisclosed institutional investors. Atyr said current venture capital investors and a current public investment fund took part in the raise as well. San Diego-based Atyr Phrama is a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address rare diseases.
- Chiasma snags $70 mln Series E
Chiasma Inc has received $70 million in Series E financing. The investors included Rock Springs Capital, Sofinnova Ventures, MPM Capital, F2 Capital, 7 Med Health Ventures, Abingworth and ARCH Venture Partners. Headquartered in Newton, Massachusetts and Jerusalem, Chiasma is a biopharmaceutical firm focused on treating acromegaly.
- Lineagen racks up $15.8 mln Series C
Salt Lake City-based Lineagen Inc, a molecular diagnostics company focused on childhood development disorders, has closed $15.8 million in Series C funding. The investors included HealthQuest Capital, Petra Capital Partners, Mountain Group Partners. Sanderling Ventures, Signal Peak Ventures, PrairieGold Venture Partners, Mesa Verde Venture Partners and KickStart Ventures. In addition to the funding, Dr. David S. Kabakoff, a partner at HeathQuest Capital and David Fitzgerald of Petra Capital have been added to Lineagen's board of directors.
Box debuts, but life sciences continue to rule new IPOsA total of eight VC-backed IPOs debuted in January, raising more than $759 million in proceeds during the month, with all but one in life sciences